Catalent Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Catalent's transformation from a public company into a Novo Holdings-owned private enterprise, tied to a strategic manufacturing acquisition by an affiliated drugmaker, is the essential fact for understanding its ownership. In December 2024, Novo Holdings, the investment arm associated with the Novo Nordisk Foundation, took Catalent private for 16.5 billion dollars at 63.50 dollars per share, ending its public listing, and in a linked transaction sold three major fill-finish manufacturing sites to the affiliated drugmaker Novo Nordisk for 11.7 billion dollars. This was no ordinary take-private: the fill-finish sites gave Novo Nordisk badly needed injectable-manufacturing capacity amid surging demand for its weight-loss and diabetes drugs, a strategic rationale that shaped the whole transaction and materially reshaped Catalent's asset perimeter. What ownership now represents is a privately held contract development and manufacturing organization owned by a long-horizon investor, offering biologics, oral-dosage, clinical-supply and consumer-health services, minus the transferred sites. For any investor, the practical reality is that Catalent no longer exists as a public investment; its ownership passed to Novo Holdings, part of its capacity went to Novo Nordisk, and value now accrues to those private owners rather than public shareholders. The relevant considerations are Novo Holdings' investment in and development of the remaining business and its relationship with the Novo group, not any ongoing Catalent equity, which ended with the 2024 take-private.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Catalent has no public shareholders; Novo Holdings took the company private in December 2024 at 63.50 dollars per share, so the relevant analysis concerns its private owners rather than a traded security. In its final full fiscal year as a public company, Catalent generated about 4.4 billion dollars of revenue as a leading contract development and manufacturing organization, and Novo Holdings paid 16.5 billion dollars for the company. The transaction's logic was partly strategic: in a linked deal, Novo Holdings sold three fill-finish manufacturing sites to the affiliated drugmaker Novo Nordisk for 11.7 billion dollars, giving Novo Nordisk critical injectable-manufacturing capacity amid soaring demand for its weight-loss and diabetes drugs. The remaining Catalent business, a contract developer and manufacturer serving pharmaceutical clients with biologics, oral-dosage, clinical-supply and consumer-health services, is now owned by Novo Holdings as a long-horizon private investor. The appeal for its owners is a leading position in the attractive, growing pharmaceutical-outsourcing market, freed from public scrutiny to invest, though the removal of the fill-finish sites reshaped the asset base, and the business competes against large, capable rivals. For investors, Catalent is no longer accessible through public markets, and its value accrues to Novo Holdings and, through the transferred sites, to Novo Nordisk, rather than to public shareholders, with the take-private having served both an investment and a strategic manufacturing purpose for the affiliated Novo group.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Catalent | Brand | Drug development and manufacturing services |
| OneBio Suite | Platform | Integrated biologics development and manufacturing |
| Zydis | Technology | Fast-dissolve oral dosage platform |
| OptiForm Solution Suite | Platform | Formulation and delivery screening |
| OptiGel | Technology | Softgel formulation and manufacturing |
| Vegicaps | Technology | Plant-based capsule delivery |
| GPEx | Technology | Cell-line engineering platform |
| SMARTag | Technology | Antibody-drug conjugate platform |
| Paragon Gene Therapy | Business | Viral-vector development and manufacturing |
| Metrics Contract Services | Business | Oral development and manufacturing |
Portfolio Analysis
Catalent's competitive strength lies not in consumer brands but in a broad portfolio of proprietary drug-development and delivery technologies that make it a leading partner to pharmaceutical companies, capabilities now owned by Novo Holdings. Its technologies span the development and manufacturing of medicines: the Zydis fast-dissolve oral platform, the OptiForm formulation-screening suite, OptiGel and Vegicaps softgel and capsule technologies, the GPEx cell-line engineering platform and SMARTag antibody-drug-conjugate technology in biologics, and the OneBio Suite for integrated biologics development, along with gene-therapy manufacturing through Paragon and oral development through Metrics. The strategy, as a contract development and manufacturing organization, is to offer pharmaceutical clients a comprehensive set of development and manufacturing services and proprietary delivery technologies, from early formulation through commercial manufacturing, becoming an embedded, hard-to-replace partner in getting medicines made and delivered. Catalent's competitive strength lies in the breadth and proprietary nature of these technologies, its scale and range of services across biologics, oral dosage and consumer health, and the deep, sticky relationships it builds with clients whose products depend on its capabilities. Its competitive identity is that of a leading, technology-rich contract development and manufacturing organization, and under Novo Holdings' ownership those capabilities continue to serve pharmaceutical clients, though the transfer of fill-finish sites to Novo Nordisk reshaped its manufacturing footprint, with its competitive position now developed within the private Novo group rather than as an independent public company.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Catalent ★ | Novo Holdings | $4.379B FY2024 | Contract development manufacturing and drug-delivery provider |
| Thermo Fisher Scientific | N/A | $45B FY2025 | Life-science tools and Patheon manufacturing owner |
| Lonza Group | N/A | $8B FY2025 | Global biologics and advanced-therapy manufacturer |
| Samsung Biologics | Samsung C&T and Samsung Electronics | $4B FY2025 | Large-scale biologics manufacturer |
| WuXi Biologics | N/A | $3B FY2025 | Global biologics contract research and manufacturing provider |
Competitive Analysis
Catalent competes in pharmaceutical contract development and manufacturing, an attractive, growing market populated by large, capable rivals, and it does so now under Novo Holdings' ownership. Its competitors include the life-science tools and manufacturing giant Thermo Fisher Scientific through its Patheon business, the biologics and advanced-therapy manufacturer Lonza Group, the large-scale biologics producer Samsung Biologics, and the global provider WuXi Biologics, all substantial competitors in pharmaceutical outsourcing. Catalent's competitive footing rests on the breadth and proprietary nature of its development and delivery technologies, its scale and range of services across biologics, oral dosage and consumer health, and the deep, sticky client relationships it builds as an embedded manufacturing and development partner. The pressures it faces are competition from large, well-resourced rivals like Thermo Fisher and Lonza, the reshaping of its asset base after the transfer of fill-finish sites to Novo Nordisk, the capital intensity of pharmaceutical manufacturing, and the demands of serving pharmaceutical clients across complex, regulated processes. As a Novo Holdings-owned company, Catalent competes as a leading, technology-rich contract development and manufacturing organization within the private Novo group, and its competitive prospects depend on maintaining its technological breadth and client relationships and investing in its capabilities under long-horizon private ownership, its competitive position now shaped by Novo Holdings' strategy and its relationship with the broader Novo group rather than by the independent competitive efforts of a public company, which ended with the 2024 take-private.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Novo Holdings acquisition of Catalent | $16.5B | 2024 | Took Catalent private at $63.50 per share |
| Metrics Contract Services | $475M | 2022 | Added oral development and manufacturing capacity |
| Bettera Holdings | $1.0B | 2021 | Expanded consumer-health manufacturing |
| MaSTherCell | $315M | 2020 | Added cell-therapy development and production |
| Paragon Bioservices | $1.2B | 2019 | Built a gene-therapy manufacturing platform |
Acquisitions Analysis
Catalent's history is one of acquisition-built growth that culminated in its own acquisition by Novo Holdings. Created in 2007 when Blackstone acquired Cardinal Health's pharmaceutical technologies and services operations, Catalent returned to public markets in 2014 and then expanded aggressively through acquisitions to build capabilities in high-growth areas: Paragon Bioservices in 2019 for 1.2 billion dollars built a gene-therapy manufacturing platform, MaSTherCell in 2020 for 315 million added cell-therapy production, Bettera Holdings in 2021 for 1.0 billion strengthened consumer-health manufacturing, and Metrics Contract Services in 2022 for 475 million added oral development capacity. These deals built Catalent into a broad, technology-rich contract development and manufacturing organization. The defining transaction, however, was Catalent becoming the target: Novo Holdings completed its 16.5-billion-dollar take-private in December 2024, and in a linked deal transferred three fill-finish sites to the affiliated Novo Nordisk for 11.7 billion dollars, reshaping the asset perimeter. Value creation involving Catalent now depends not on its own acquisitions but on Novo Holdings' ownership and the strategic value the transaction delivered to the Novo group. The relevant corporate action is the Novo Holdings take-private and the linked site transfer, an arc from an acquisition-built public company to a privately held enterprise whose fill-finish capacity strategically served an affiliated drugmaker, ending Catalent's independent public existence and its own acquisitive expansion.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Catalent's corporate structure ran from a private-equity carve-out through public listing and acquisitive expansion to a Novo Holdings take-private that also reshaped its assets. Blackstone created Catalent in 2007 by acquiring Cardinal Health's pharmaceutical technologies and services operations, and the company returned to public markets in 2014 before expanding through acquisitions, Paragon, MaSTherCell, Bettera and Metrics, that broadened its development and manufacturing capabilities. Its structure was then transformed by ownership change: Novo Holdings took Catalent private in December 2024 for 16.5 billion dollars, delisting it, and in a linked transaction sold three major fill-finish sites to the affiliated Novo Nordisk for 11.7 billion dollars, materially changing the asset perimeter. The resulting structure is a privately held contract development and manufacturing organization owned by Novo Holdings, minus the transferred fill-finish capacity, connected to the broader Novo group. That structural arc, a private-equity creation taken public, expanded through acquisition, and then taken private in a deal that redirected key manufacturing capacity to an affiliated drugmaker, defines Catalent's corporate history. Its structure today is that of a Novo Holdings-owned private enterprise rather than an independent public company, and its structural future is shaped by Novo Holdings' ownership and its relationship with the Novo group, its public-company structure having ended with the 2024 take-private and the linked reshaping of its manufacturing footprint.
Ownership History
Ownership History Analysis
Catalent's history runs from a Cardinal Health carve-out to a Novo Holdings-owned private enterprise. Blackstone created Catalent in 2007 by acquiring Cardinal Health's pharmaceutical technologies and services operations, and the company returned to public markets in 2014, building itself into a leading contract development and manufacturing organization through both proprietary technologies like Zydis and OptiForm and a series of acquisitions, Paragon in gene therapy, MaSTherCell in cell therapy, Bettera in consumer health, and Metrics in oral development, that expanded its capabilities across high-growth areas. Its independent public chapter ended in December 2024, when Novo Holdings took the company private for 16.5 billion dollars and, in a linked transaction, transferred three major fill-finish sites to the affiliated Novo Nordisk for 11.7 billion dollars, giving the drugmaker critical manufacturing capacity for its weight-loss and diabetes drugs. Generating about 4.4 billion dollars of revenue in its final public year with roughly 16,900 employees, Catalent is now a privately held Novo Holdings company. Its history is that of a private-equity creation that built broad drug-development and manufacturing capabilities as a public company and was ultimately taken private in a transaction that both created a long-horizon private enterprise and strategically served an affiliated drugmaker's manufacturing needs, its independent public existence ending with the 2024 Novo Holdings take-private that reshaped its assets and ownership.
Ownership Explained
Catalent is a leading contract developer and manufacturer of pharmaceuticals and drug-delivery technologies that, since December 2024, is a privately held company owned by Novo Holdings rather than a public issuer. A Somerset, New Jersey business created in 2007 from Cardinal Health assets, Catalent generated about 4.4 billion dollars of revenue in its final full fiscal year as a public company and employed roughly 16,900 people, offering biologics, oral-dosage, clinical-supply and consumer-health development and manufacturing services under technologies like Zydis, OptiForm and OptiGel. Novo Holdings took the company private for 16.5 billion dollars at 63.50 dollars per share, and, in a linked transaction, sold three major fill-finish manufacturing sites to the affiliated drugmaker Novo Nordisk for 11.7 billion dollars, materially reshaping the asset perimeter.
Catalent's ownership now rests with Novo Holdings, the investment arm behind the Novo Nordisk Foundation, following a take-private that also served a strategic purpose for the affiliated drugmaker Novo Nordisk. The acquisition removed Catalent from public markets and, crucially, enabled Novo Nordisk to acquire three fill-finish sites, valuable manufacturing capacity at a time when demand for injectable weight-loss and diabetes drugs strained supply. For the remainder of Catalent, private ownership under Novo Holdings offers a long-horizon owner and freedom from public scrutiny to invest in its drug-development and manufacturing services. There is no longer a Catalent equity for public investors; the relevant stakeholders are Novo Holdings, the affiliated Novo Nordisk that gained manufacturing sites, and management, with value accruing to those private owners.